Valneva SE (VALN) Capital Expenditures (2021 - 2026)
Valneva SE (VALN) posted Capital Expenditures of -$289174.2 for Q1 2026, down 103.2% sequentially from $9.0 million in Q4 2025, and up 80.39% YoY from -$160303.6 in Q1 2025.
Analysis
Valneva SE (VALN) Capital Expenditures (2021 - 2026) Analysis & Trends
Valneva SE has reported Capital Expenditures for 6 years, with the latest figure at -$289174.2 in Q1 2026.
- Quarterly Capital Expenditures rose 80.39% year-over-year to -$289174.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 63.7% YoY) and the FY2025 annual result came in at $5.1 million, down 65.71% from the prior year.
- Capital Expenditures declined to -$289174.2 in Q1 2026 per VALN's latest filing, from $9.0 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $7.8 billion in Q3 2023 and troughed at -$7.8 billion in Q2 2023.
- A 5-year average of $3.6 million and a median of -$1.4 million in 2025 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 118555.13% in 2023, down 111166.8% in 2023.
- Over 5 years, Capital Expenditures stood at $52.8 million in 2022, then sank by 53.95% to $24.3 million in 2023, then grew by 4.97% to $25.5 million in 2024, then plunged by 64.61% to $9.0 million in 2025, then sank by 103.2% to -$289174.2 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$289174.2, $9.0 million, and -$780928.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | -397,527.75 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -397,527.75 |
| Mar 31, 2026 | -289,174.18 |
| Dec 31, 2025 | -1.26 Mn |
| Sep 30, 2025 | -780,928.80 |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | -4.12 Mn |
| Sep 30, 2024 | -6.48 Mn |
| Jun 30, 2024 | 424,293.71 |
| Mar 31, 2024 | -4.89 Mn |
| Dec 31, 2023 | -6.32 Mn |
| Sep 30, 2023 | 7.79 Bn |
| Jun 30, 2023 | -7.80 Bn |
| Mar 31, 2023 | -4.13 Mn |
| Dec 31, 2022 | -6.91 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -7.01 Mn |
| Mar 31, 2022 | -10.53 Mn |
| Dec 31, 2021 | -26.60 Mn |
| Sep 30, 2021 | -35.14 Mn |